1. A prokaryote system optimization for rMEPLox expression: A promising non-toxic antigen for Loxosceles antivenom production.
- Author
-
Saavedra-Langer R, Costa TGF, Lima SA, Costal-Oliveira F, Martins CA, Machado-de-Ávila RA, Minozzo JC, Soccol VT, Guerra-Duarte C, Kalapothakis E, and Chávez-Olórtegui C
- Subjects
- Animals, Antivenins biosynthesis, Antivenins genetics, Antivenins immunology, Antivenins isolation & purification, Mice, Inbred BALB C, Phosphoric Diester Hydrolases biosynthesis, Phosphoric Diester Hydrolases genetics, Phosphoric Diester Hydrolases immunology, Phosphoric Diester Hydrolases isolation & purification, Recombinant Proteins biosynthesis, Recombinant Proteins genetics, Recombinant Proteins immunology, Recombinant Proteins isolation & purification, Spider Venoms biosynthesis, Spider Venoms genetics, Spider Venoms immunology, Spider Venoms isolation & purification, Mice, Escherichia coli genetics, Escherichia coli metabolism, Gene Expression, Spiders genetics
- Abstract
Loxoscelism is the most dangerous araneism form in Brazil and antivenom therapy is the recommended treatment. Antivenom is produced by horse immunization with Loxosceles spider venom, which is toxic for the producer animal. Moreover, due to the high amount of venom required for horse hyperimmunization, new strategies for antigens obtention have been proposed. In this sense, our research group has previously produced a non-toxic recombinant multiepitopic protein derived from Loxosceles toxins (rMEPLox). rMEPLox was a successful immunogen, being able to induce the production of neutralizing antibodies, which could be used in the Loxoscelism treatment. However, rMEPLox obtention procedure requires optimization, as its production needs to be scaled up to suit antivenom manufacture. Therefore, an effective protocol development for rMEPlox production would be advantageous. To achieve this objective, we evaluated the influence of different cultivation conditions for rMEPLox optimum expression. The optimum conditions to obtain large amounts of rMEPlox were defined as the use of C43(DE3)pLysS as a host strain, 2xTY medium, 0.6 mM IPTG, biomass pre induction of OD
600nm = 0.4 and incubation at 30 °C for 16 h. Following the optimized protocol, 39.84 mg/L of soluble rMEPLox was obtained and tested as immunogen. The results show that the obtained rMEPLox preserved the previously described immunogenicity, and it was able to generate antibodies that recognize different epitopes of the main Loxosceles venom toxins, which makes it a promising candidate for the antivenom production for loxoscelism treatment., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF